MA42399B1 - Composés inhibiteurs de la voie de signalisation de notch - Google Patents
Composés inhibiteurs de la voie de signalisation de notchInfo
- Publication number
- MA42399B1 MA42399B1 MA42399A MA42399A MA42399B1 MA 42399 B1 MA42399 B1 MA 42399B1 MA 42399 A MA42399 A MA 42399A MA 42399 A MA42399 A MA 42399A MA 42399 B1 MA42399 B1 MA 42399B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- signaling pathway
- notch signaling
- inhibit
- hair cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne les composés suivants, ou des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques contenant lesdits composés utilisables en tant qu'inhibiteurs de la voie de signalisation de notch pour le traitement de cancers désignés, de la surdité neurosensorielle provoquée par la perte de cellules ciliées du système auditif, et pour induire la génération de cellules ciliées du système auditif.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562189393P | 2015-07-07 | 2015-07-07 | |
EP16741742.7A EP3319967B1 (fr) | 2015-07-07 | 2016-07-01 | Composés inhibiteurs de la voie de signalisation de notch |
PCT/US2016/040612 WO2017007702A1 (fr) | 2015-07-07 | 2016-07-01 | Composés inhibiteurs de la voie de signalisation de notch |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42399A MA42399A (fr) | 2018-05-16 |
MA42399B1 true MA42399B1 (fr) | 2019-08-30 |
Family
ID=56507825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42399A MA42399B1 (fr) | 2015-07-07 | 2016-07-01 | Composés inhibiteurs de la voie de signalisation de notch |
Country Status (42)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
CA3029281A1 (fr) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Formulations otiques a base de triglycerides et leurs utilisations |
US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
AR111252A1 (es) * | 2017-03-24 | 2019-06-19 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos |
MA53645A (fr) * | 2018-09-21 | 2021-12-29 | Novartis Ag | Composés d'isoxazole carboxamide et leurs utilisations |
EP3860562A1 (fr) | 2018-10-02 | 2021-08-11 | Frequency Therapeutics, Inc. | Compositions pharmaceutiques comprenant des agents thérapeutiques otiques et procédés associés |
US20220008433A1 (en) * | 2018-11-30 | 2022-01-13 | Massachusetts Eye And Ear Infirmary | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells |
EP3952854A1 (fr) | 2019-04-08 | 2022-02-16 | Frequency Therapeutics, Inc. | Association de chir99021 et d'acide valproïque pour traiter une perte auditive |
US20230118097A1 (en) * | 2020-01-22 | 2023-04-20 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
WO2023200017A1 (fr) * | 2022-04-11 | 2023-10-19 | Prism BioLab Co., Ltd. | Nouveaux composés à cycles fusionnés à sept éléments |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
RU2440342C2 (ru) | 2006-03-27 | 2012-01-20 | Ф.Хоффманн-Ля Рош Аг | МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ |
AU2009212135B2 (en) | 2008-02-07 | 2014-08-21 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
US10143711B2 (en) | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
US9125894B2 (en) | 2010-10-06 | 2015-09-08 | Massachusetts Eye & Ear Infirmary | Methods for promoting reinnervation of auditory hair cells |
AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
WO2014039781A1 (fr) * | 2012-09-07 | 2014-03-13 | Massachusetts Eye & Ear Infirmary | Traitement de la perte auditive |
US20140134136A1 (en) | 2012-11-02 | 2014-05-15 | Massachusetts Eye And Ear Infirmary | Compositions and methods for auditory therapy |
JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
RU2757276C2 (ru) * | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
-
2016
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/fr active Application Filing
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/fr active Active
- 2016-07-01 CA CA2987431A patent/CA2987431C/fr active Active
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 MX MX2017016555A patent/MX2017016555A/es active IP Right Grant
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/fr unknown
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active IP Right Grant
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
- 2018-05-17 HK HK18106380.5A patent/HK1247187B/zh unknown
-
2019
- 2019-06-28 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42399B1 (fr) | Composés inhibiteurs de la voie de signalisation de notch | |
MA44674A (fr) | Inhibiteurs de bromodomaine | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
MX2015017964A (es) | Inhibidores de bromodominio. | |
MA38099B1 (fr) | Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MX368017B (es) | Compuestos de indazol como agonistas del receptor de 5-ht4. | |
EA201890412A1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
MA45905B1 (fr) | Composition pour traiter une blépharite contenant du terpinène-4-ol | |
MA39153A1 (fr) | Nouveaux composés hétérocycliques | |
MA38206A1 (fr) | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
MA38207A2 (fr) | Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase | |
MA38280B1 (fr) | Composes 1,2,3,4-tetrahydroisoquinoleine substitues inhibiteurs de la proteine arginine-methyltransferase 5 | |
MA38549A1 (fr) | Activateur d'inhibiteurs de l'homologue 2 de zeste |